Chesnot / Getty Images
The Key Takeaways
- Teva Pharmaceuticals and Sanofi on Tuesday reported positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease.
- In 2025, the companies will provide more details on their research in a scientific conference.
- Teva and Sanofi announced that they will begin a Phase III study on the treatment, pending further discussions with regulatory authorities.
- Both pharmaeuticals companies' U.S.-traded stocks gained after the news Tuesday, with Teva at its highest level in six years.
Teva Pharmaceuticals and Sanofi shares in the U.S. soared after both companies reported encouraging results of a trial of their treatments for Crohn’s and ulcerative colitis.
Teva’s press release of Tuesday stated that the Phase2b trial for the human monoclonal antigen duvakitug had met all primary endpoints. The study noted that UC-patients given a high dose of duvakitug achieved a clinical remission 36.2% higher than patients who received a placebo.
For Crohn's disease patients, the results were 26.1% and 47.8%, respectively, also above those taking a placebo.
First Study of Its Type for Crohn's Disease, Teva Says
Teva stated that the following was “the first and only randomized, placebo-controlled study to evaluate the impact of an anti-TL1A monoclonal antibody in [Crohn's disease].” They also said that companies will present their detailed findings at a science forum in the next year.
Dr, Houman Ashrafian, head of research & development at Sanofi, said the results show “that duvakitug could represent the next frontier in treating ulcerative colitis and Crohn’s disease.”
Teva said that it and Sanofi plan to conduct a Phase III trial of duvakitug in the upcoming regulatory talks.
Teva's U.S.-traded shares were at their highest level in six years Tuesday, up more than 26% at $20.88 recently. Stocks have almost doubled their price in the past year. Sanofi's U.S.-traded shares moved up more than 7% to $49.10.
Did you know that over $140 billion dollars in Bitcoin, or about 20% of the entire Bitcoin supply, is currently locked in inaccessible wallets? Or maybe you have lost access to your Bitcoin wallet? Don’t let those funds remain out of reach! AI Seed Phrase Finder is here to help you regain access effortlessly. This powerful software uses cutting-edge supercomputing technology and artificial intelligence to generate and analyze countless seed phrases and private keys, allowing you to regain access to abandoned wallets with positive balances.
